Past Recipients NOC Young Investigator Award

1st place
- Laura Sasportas - "Single cell metabolomics in circulating tumor cells"
2nd place - Matthias Eiber - "Detection rate for a novel 68Ga-PSMA PET-ligand in patients with biochemical recurrence of prostate cancer using PET/CT and PET/MR imaging"
3rd place (tie) - Carmen Vigil - "Prediction of recurrence and survival analysis after radiotherapy of glioblastoma using 11C-Methionine PET/CT and MR"
3rd place (tie) - Harshad Kulkarni - "First clinical results with Lu-177 PSMA-TUM1 for the treatment of castrate-resistant metastatic prostate cancer"

1st Place
- Nerissa Therese Villegas - "Correlative imaging of pancreatic ductal adenocarcinoma over-expressing CA19.9 antigen"
2nd Place
- Meena Kumar - "Characterization of physiological 18F-FSPG uptake in healthy volunteers and comparison to 18F-FDG"
3rd Place
- Yoann Petibon - "MR-based motion correction in simultaneous PET/MR liver imaging"

1st Place
- Markus Hartenbach - "FEC-PET/MRI in primary prostate cancer. Results of a prospective clinical trial"
2nd Place - Camilla Bardram Johnbeck - "Synergistic effect of combined treatment with 177Lu-DOTATATE and Everolimus in neuroendocrine tumors as monitored by 18F-FDG-PET: Studies in human neuroendocrine xenografts"
3rd Place - Jae Pil Hwang - "PET-MR can predict survival and response in advanced hepatocellular carcinoma patients treated with sorafenib"

1st Place - Clemens, Kratochwil - "Regional 213Bi-DOTATOC peptide receptor alpha-therapy in patients with neuroendocrine liver metastases refractory to beta-radiation"
2nd Place - Andrei Iagaru - "Combined 18F NaF and 18F FDG PET/CT: Initial results of a multi-center trial"
3rd Place - Guido Davidzon - "Comparison of four different imaging response criteria in patients with Hodgkin and non-Hodgkin lymphoma using PET/CT"

1st Place - Félix-Nicolas Roy, MD, FRCPC - Predictive value of (16 alpha[18-F]-fluoroestradiol) FES-PET in recurrent estrogen receptor positive (ER+) breast cancer.
2nd Place - S. Nafees Rizvi - Biodistribution and radiation dosimetry of 90Y-ibritumomab-tiuxetan using 89Zr-ibritumomab-tiuxetan and PET in patients with relapsed B-cell non-Hodgkin’s lymphoma.
3rd Place - Alexander Haug - 68Ga-DOTATATE PET/CT for the early prediction of response to peptide receptor radionuclide therapy in patients with well differentiated neuroendocrine tumours.

1st Place – Mirwais Wardak - #103 FLT kinetics predict survival in brain tumor therapy 
2nd Place (tie) – Saoussen Belhassen - #104 Comparative methods for 18F-FDG PET-based delineation of target volumes in non-small-cell lung cancer  
2nd Place (tie) - Jolanta Kunikowska - #106 Clinical results of PRRT with 90Y-DOTATATE and 90Y/177Lu- DOTATATE-what is better for therapy?